|
Evolving from its traditional role as the world’s supplier of affordable generics to a research-driven, technology-integrated global healthcare powerhouse, Indian pharmaceutical industry is undergoing a profound transformation.
Indian pharmaceutical companies are increasingly investing in innovation, biosimilars, complex generics, and cutting-edge research. The integration of artificial intelligence, data analytics, and genomics is opening new frontiers in drug discovery, personalized medicine, and precision healthcare. These advancements are positioning India as a leader not just in manufacturing but also in the development of next-generation therapies and solutions.
At the same time the active pharmaceutical ingredients (API) industry in India also stands at the threshold of a transformation with backward integration and reduced import dependence, growth in high-value, niche APIs, improved regulatory compliance and quality focus, sustainability & Green API manufacturing, digital & virtual API supply chain models.
Impacted by global supply chain dynamics, shifting regulatory landscapes, and the desire for self-reliance, the API industry in the country is at a watershed moment.
Traditionally reliant on imports, especially from China, India has made significant strides in boosting its domestic API manufacturing capabilities.
India’s unparalleled manufacturing scale, cost efficiency, and deep reservoir of scientific talent provide it with a competitive edge. The country’s skilled workforce is driving innovation and ensuring the highest standards of quality and compliance. This blend of scale and expertise enables India to meet both domestic healthcare needs and the growing demands of international markets.
Continued government support through schemes like the PLI, coupled with a focus on sustainability and green chemistry, is fostering an environment conducive to long-term growth. The sector’s commitment to environmental responsibility and sustainable manufacturing practices is enhancing its global reputation and appeal.
India’s strategic collaborations with global pharmaceutical giants, research institutions, and regulatory bodies are expanding its footprint in regulated markets such as the US, EU, and Japan. These partnerships are facilitating technology transfer, knowledge exchange, and access to new markets, further accelerating the industry’s growth trajectory.
Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030 and US$ 450 billion by 2047, reflecting the country’s expanding role in global pharmaceutical production. The country’s pharmaceutical industry stands ready to shape the future of global healthcare, setting new benchmarks in accessibility, affordability, and advancement.
CPHI & PMEC India 2025
Even as the pharma sector of the country is thus undergoing tremendous transformation, the 18th edition of CPHI & PMEC India 2025, India’s largest exhibition on pharmaceutical industry will be unfolding from November 25 - 27, 2025, at the India Expo Mart, Greater Noida, Delhi NCR.
Organized by Informa Markets in India, the event will bring together over 2,000 exhibitors and more than 35,000 industry professionals, buyers, and investors from India, Southeast Asia, and across the globe.
The 2025 edition will feature the complete pharmaceutical value chain under one roof, encompassing formulations, APIs, excipients, packaging, machinery, and contract services, offering unparalleled opportunities for business networking, B2B matchmaking, and market insights.
CPHI & PMEC India 2025 serves as an ideal platform for strengthening collaboration, knowledge exchange, and strategic partnerships that will shape the future of India’s pharmaceutical landscape.
The upcoming edition will focus on key industry themes such as API self-reliance, sustainability, digitalization, and exports, highlighting India’s transition toward innovation-driven growth. The event will showcase cutting-edge solutions in clean manufacturing, ESG compliance, and Pharma 4.0 technologies, aligning with the evolving needs of a future-ready pharma ecosystem. Visitors can expect exciting product launches and breakthrough technology innovations, highlighting India’s growing capability in sustainable and high-value pharma manufacturing.
This year’s edition will also host the Pharma Leaders Roundtable, Women in Pharma Roundtable, the CPHI Pharma Awards, and the Pharma Connect Congress, offering a platform for policy dialogues, leadership exchange, and innovation-driven discussions.
The three-day event will also feature a comprehensive line-up of knowledge-led conferences and leadership dialogues, designed to drive strategic discussions and actionable insights for the pharmaceutical community.
The event will see participation from leading exhibitors such as Dr. Reddy’s Laboratories, Hetero Labs, Oceanic Pharmachem, Akums Drugs & Pharmaceuticals, Morepen Laboratories, MSN Laboratories, Capsugel Healthcare, Biocon, and Jubilant Ingrevia.
CPHI stands as a comprehensive platform, unveiling the latest advancements, technologies, and trends in the dynamic realms of the pharmaceutical and healthcare sectors. The exhibition will showcase a wide range of offerings including APIs, excipients, finished dosage forms, machinery and equipment, cleanroom and processing technologies, contract services, intermediates, and related specialties.
PMEC India offers a specific highlight on pharma machinery and equipment, packaging, equipment and supplies, process automation & controls, testing and measurement, validation, automation & robotics, processing equipment, RFID companies, and many more segments under one roof.
PMEC India will feature top players including ACG Pam Pharma Technologies, Cadmach Machinery, Ace Technologies & Packaging Systems, Parle Global Technologies, Klenzaids Contamination Controls, Gansons, Elmach Packages (India), NPM Machinery and Snowbell Machines.
In addition to the exhibition, attendees will have access to talks, panels and presentations on regulatory developments, market trends, manufacturing excellence, and technology adoption.
Supported by key industry associations such as Pharmexcil, International Pharmaceutical Excipients Council (IPEC) India, Bulk Drug Manufacturers Association of India (BDMAI), and Organization of Pharmaceutical Producers of India (OPPI), along with participation from regulatory authorities and policymakers, the 2025 edition reinforces its position as a credible platform for policy advocacy, industry collaboration, and sustainable business growth.
CPHI & PMEC India 2024
CPHI & PMEC India 2024 had concluded on a remarkable high at the India Expo Centre. Over three action-packed days from November 26 to 28, the event brought together groundbreaking innovations in pharmaceutical machinery, analytical instruments, laboratory technologies, equipment, ingredients, and more.
The dynamic exhibits, lively forums, and thought-provoking conferences generated an overwhelmingly positive response. With more than 60,000 attendees from over 120 countries, this year’s event exceeded expectations, setting new records for both attendance and exhibitors, with more than 2,000 exhibitors showcasing their latest advancements.
Additionally, CPHI & PMEC India 2024 garnered significant recognition with a mention from Prime Minister Narendra Modi on Twitter, spotlighting the pharmaceutical industry and how shows like the CPHI & PMEC India expo enable the sector’s growth. The article quoted was: India poised to become pharmacy of the world. This endorsement underscored the event’s growing impact and elevates it to new heights of excellence.
The show opened with an august gathering, featuring prominent figures such as K. Raja Bhanu, Director General, Pharmexcil; Harish K. Jain, President, FOPE; Namit Joshi, Vice Chairman, Pharmexcil; AVPS Chakravarthy, Global Ambassador, WPO; Rakesh Kumar, Chairman, India Expo Mart Limited (IEML); Yogesh Mudras, Managing Director, Informa Markets in India; Adam Anderson, Executive Vice President - Pharma, Informa Markets B.V.; and Rahul Deshpande, Senior Group Director, Informa Markets in India.
The dignitaries commended the event’s contribution to advancing India’s pharmaceutical sector and fostering global collaboration, reinforcing the expo’s importance as a cornerstone for innovation, dialogue, and growth in the industry.
The event also featured a stellar lineup of exhibitors, including leading names like Dr. Reddy’s Laboratories Ltd, Biocon Ltd, Glenmark Lifesciences Ltd, Morepen Laboratories Ltd, Hetero Labs Limited, Lupin Ltd, and Merck Life Science Pvt. Ltd. The PMEC pavilion showcased cutting-edge pharmaceutical manufacturing technologies, with exhibitors like ACG, Accupack Engineering, and Fette India spotlighting the latest advancements in equipment and innovation.
The expo garnered strong support from industry associations, including CIPI, FOPE, IPA, IPEC India, OPPI, Pharmexcil and PSCI, further solidifying its position as a leading and highly anticipated event in the pharmaceutical industry.
Highlighting India’s growing leadership in the global market, Yogesh Mudras said, “The Indian pharmaceutical industry continues to be a global leader in manufacturing excellence, ranking 3rd in production by volume and 14th by value, contributing 1.72 per cent to the nation’s GDP. India’s leadership is driven by cost-effective manufacturing, R&D costs 87 per cent lower than developed markets, and a skilled workforce. CPHI & PMEC India has been a catalyst for this growth, evolving into a global hub that represents the strength of the pharma industry and India’s flourishing domestic and R&D sectors. This year’s edition, the largest ever, marked a standout success, reinforcing India’s role in shaping the future of global healthcare and fostering impactful synergies.”
Beyond the business exchanges on the show floor, several high-impact sessions elevated the experience for attendees.
The Pharma Leaders Roundtable was one of the standout events of CPHI & PMEC India 2024, bringing together distinguished leaders for impactful discussions. This exclusive, closed-door forum explored unprecedented opportunities and challenges arising from shifting global supply chain dynamics and evolving manufacturing trends. Key themes included capitalizing on geopolitical shifts, driving technological innovation, addressing infrastructure and regulatory hurdles, advancing drug biotransformation, and fostering sustainability in pharma.
|